MFG
MYGN icon

Mendota Financial Group’s Myriad Genetics MYGN Stock Holding History

Mendota Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$83 – 874
2024
Q3 		$83 Buy
+3
New +$81 ﹤0.01% 999

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Mendota Financial Group's MYGN Position: Q4 2024 in Review

Mendota Financial Group sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 3 shares — an estimated $83 sold.

Mendota Financial Group first reported a position in MYGN in Q3 2024 and held it in 1 quarter. The position peaked at $83 in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Mendota Financial Group reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 3 Myriad Genetics shares in Q4 2024, an estimated $83.
  • Mendota Financial Group first reported a position in Myriad Genetics in Q3 2024 and held it in 1 quarter.
  • Mendota Financial Group's Myriad Genetics position peaked at $83 in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.